CARA Cara Therapeutics Inc

Price (delayed)

$10.95

Market cap

$588.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.26

Enterprise value

$543.99M

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is ...

Highlights
CARA's debt is down by 37% year-on-year and by 13% since the previous quarter
Cara Therapeutics's EPS has increased by 30% from the previous quarter
CARA's gross profit has soared by 97% from the previous quarter but it has plunged by 62% YoY
The revenue has surged by 89% since the previous quarter but it has dropped by 60% year-on-year
The quick ratio has declined by 24% year-on-year

Key stats

What are the main financial stats of CARA
Market
Shares outstanding
53.73M
Market cap
$588.3M
Enterprise value
$543.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.87
Price to sales (P/S)
12.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.13
Earnings
Revenue
$48.89M
EBIT
-$66.35M
EBITDA
-$64.74M
Free cash flow
-$45.47M
Per share
EPS
-$1.26
Free cash flow per share
-$0.85
Book value per share
$3.81
Revenue per share
$0.91
TBVPS
$4.23
Balance sheet
Total assets
$226.57M
Total liabilities
$22.15M
Debt
$2.82M
Equity
$204.42M
Working capital
$155M
Liquidity
Debt to equity
0.01
Current ratio
8.32
Quick ratio
7.86
Net debt/EBITDA
0.68
Margins
EBITDA margin
-132.4%
Gross margin
95.7%
Net margin
-135.7%
Operating margin
-137.1%
Efficiency
Return on assets
-28.8%
Return on equity
-31.5%
Return on invested capital
-35%
Return on capital employed
-32.3%
Return on sales
-135.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CARA stock price

How has the Cara Therapeutics stock price performed over time
Intraday
-2.93%
1 week
-12.82%
1 month
18.38%
1 year
-13.92%
YTD
-10.1%
QTD
19.93%

Financial performance

How have Cara Therapeutics's revenue and profit performed over time
Revenue
$48.89M
Gross profit
$46.81M
Operating income
-$67.03M
Net income
-$66.35M
Gross margin
95.7%
Net margin
-135.7%
CARA's gross profit has soared by 97% from the previous quarter but it has plunged by 62% YoY
The revenue has surged by 89% since the previous quarter but it has dropped by 60% year-on-year
CARA's net margin has surged by 62% since the previous quarter
Cara Therapeutics's operating margin has soared by 62% from the previous quarter

Growth

What is Cara Therapeutics's growth rate over time

Valuation

What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
2.87
P/S
12.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.13
Cara Therapeutics's EPS has increased by 30% from the previous quarter
The P/B is 39% lower than the 5-year quarterly average of 4.7 and 4.3% lower than the last 4 quarters average of 3.0
The revenue has surged by 89% since the previous quarter but it has dropped by 60% year-on-year
CARA's P/S is 86% below its 5-year quarterly average of 84.6 and 29% below its last 4 quarters average of 16.9

Efficiency

How efficient is Cara Therapeutics business performance
Cara Therapeutics's ROS has soared by 62% from the previous quarter
Cara Therapeutics's return on equity has increased by 29% QoQ
CARA's ROA is up by 29% QoQ
CARA's return on invested capital is up by 26% since the previous quarter

Dividends

What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CARA.

Financial health

How did Cara Therapeutics financials performed over time
The quick ratio has declined by 24% year-on-year
Cara Therapeutics's total liabilities has increased by 23% YoY and by 12% from the previous quarter
CARA's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% QoQ and by 50% YoY
CARA's debt is down by 37% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.